Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Losartan Potassium,Hydrochlorothiazide
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Received ANDA Approval for Losartan and Hydrochlorothiazide Tablets
Details : Generic of Losartan potassium and hydrochlorothiazide tablets are been approved by FDA, indicated for hypertension to lower blood pressure and to reduce the risk of stroke.
Product Name : Cozaar-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
September 30, 2023
Lead Product(s) : Losartan Potassium,Hydrochlorothiazide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Gets USFDA Nod to Market Generic Medication to Treat High Blood Pressure
Details : Losartan potassium prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure. Angiotensin II would otherwise bind to the AT1 receptor and induce vasoconstriction, raising blood pressure.
Product Name : Cozaar-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SCIENTURE Gains FDA Nod for SCN-102, Branded as Arbli (Losartan Suspension)
Details : Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
Product Name : Arbli
Product Type : Hormone
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains on Securing RCGM Approval for Erythropoietin
Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 02, 2025
Lead Product(s) : Losartan Potassium
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RFU Startup Preparing For Pivotal Clinical Trial On Novel Therapy For Sudden Cardiac Arrest
Details : Erythropoietin during cardiac arrest exerts protection by either preventing apoptosis of cardiac myocytes, smooth muscle cells, endothelial cells, or by increasing endothelial production of nitric oxide.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Losartan Potassium
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable